lenvatinib (Kisplyx)

following an abbreviated submission:

lenvatinib (Kisplyx®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment.

SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.

Lenvatinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors given in combination with a PD-1/PD-L1 inhibitor for this indication.

Medicines within this therapeutic class have been accepted under the end of life process for this indication.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.